MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6

Abstract

Key WordsHer-2-positive breast cancer • Trastuzumab resistance • MiR-129-5p • RpS6 Abstract Background/Aims: Trastuzumab is an important treatment used for patients with Her-2-positive breast cancer, but an increasing incidence of trastuzumab resistance has been observed clinically during the past decade. Aberrant microRNA (miR) expression levels are correlated with prognosis and response to trastuzumab in breast cancer. MiR-129-5p is downregulated in trastuzumab-resistant human breast cancer cells (JIMT-1), but its potential function and underlying mechanism remain unclear. Methods: Quantitative RT-PCR (qRT-PCR) was used to determine the expression levels of miR-129-5p and its potential target genes. The effects of miR-129-5p on cell responses to trastuzumab were analyzed by CCK-8 and flow cytometry assays in Her-2-positive breast cancer cells (SKBR-3 and JIMT-1). Bio-informatics analyses were performed to predict target genes of miR-129-5p, and luciferase assays were carried out to confirm the binding of miR-129-5p and rpS6. Results: MiR-129-5p, which was downregulated and predicted to target rpS6 in trastuzumab-resistant breast cancer cells, enhanced the sensitivity of breast cancer cells to trastuzumab by reducing the expression of rpS6. Moreover, the overexpression of rpS6 reversed the sensitivity of cells to trastuzumab induced by miR-129-5p. Conclusions: MiR-129-5p sensitized Her-2-positive breast cancer to trastuzumab by downregulating rpS6. These findings provide novel insights into the common role of rpS6 and its related molecular mechanisms in mediating trastuzumab-resistance in Her-2-positive breast cancers.

The Dysregulated Expression of KCNQ1OT1 and Its Interaction with Downstream Factors miR-145/CCNE2 in Breast Cancer Cells

“…Several studies have unveiled the regulatory functions of miRNAs in breast cancer. For instance, miR-129-5p was demonstrated to stimulate Her-2-positive breast cancer sensitive to trastuzumab [9]. MiR-212-5p/miR-101 was validated to exert inhibitory influences on breast cancer in some studies [10,11], while miR-1246 promoted breast cancer and its drug resistance, [12] and miR-181a had dual regulatory roles in BRCA [13].…”

Mining Prognostic Significance of MEG3 in Human Breast Cancer Using Bioinformatics Analysis

“…Breast cancer remains a leading cause of cancer-related death in women [1][2][3]. Despite increased screening and improved diagnosis and treatment of breast cancer, prognosis remains poor [4][5][6].…”

miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1

“…MicroRNAs (miRNAs) are a class of endogenous, noncoding small RNA molecules, which bind to the 3 0 untranslated region (3 0 UTR) of the target genes, resulting in mRNA degradation or transcriptional inhibition (Cai et al, 2009;Hayes et al, 2014). Studies have reported that dysregulation of miRNAs participate in various biological processes in cancers, including cell proliferation, differentiation, and apoptosis (Zhang et al, 2005;Bartel, 2009;Lu et al, 2017b). Moreover, emerging evidence has indicated that the acquired drug resistance in cancer cells could be regulated by miRNAs (Ma et al, 2010;Majumder and Jacob, 2011).…”